Compugen Ltd.

357 articles with Compugen Ltd.

• Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

  6/8/2021

  Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo®

• Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities

  6/1/2021

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that members of its senior management team will participate in a virtual event to discuss data from its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, as a monotherapy and in combination with nivolumab.

• Compugen Reports First Quarter 2021 Results

  5/13/2021

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2021.

• Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series

  5/11/2021

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that Eran Ophir, Ph.D., Vice President Research and Drug Discovery at Compugen, will participate at the Society for Immunotherapy of Cancer Targets for Cancer Immunotherapy: A Deep Dive Seminar Series.

• Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen

  5/10/2021

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that it has expanded its research collaboration with Johns Hopkins University to include studies investigating the biology of a novel myeloid target that was computationally-discovered by Compugen.

• Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021

  5/3/2021

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open.

• Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

  4/27/2021

  Peer reviewed data demonstrate synergistic effect of anti-TIGIT antibody, COM902, with PVRIG and PD-1 blockade for the treatment of cancer Phase 1 trial of COM902 monotherapy in patients with advanced malignancies is currently on track to report data in Q4 2021; Initiation of dual combination study for COM701 with COM902 expected as planned in H2 2021

• Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

  3/9/2021

  The peer-reviewed article published in Cancer Discovery, a journal of the American Association for Cancer Research Anat Cohen-Dayag, Ph.D., President and CEO of Compugen: Our discovery of PVRIG as a distinct pathway in the DNAM axis has evolved into a deep and broad understanding of this potentially foundational axis in cancer immunotherapy   [09-March-2021]  

• Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/8/2021

  Compugen Ltd.  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31 st Annual Healthcare Conference (virtual), on Tuesday, March 16 , 2021 at 10:40 AM ET.

• Compugen Reports Fourth Quarter and Full Year 2020 Results

  2/25/2021

  Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint inhibitors

• Compugen Announces Data Update from COM701 Phase 1 Clinical Trial

  2/25/2021

  Durable responses observed with COM701 in combination with Opdivo® including a confirmed complete response in a patient with prior progression on Opdivo®

• Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®

  2/22/2021

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb.

• Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021

  2/16/2021

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 before the U.S. financial markets open.

• Compugen to Present at Upcoming Investor Conferences

  11/10/2020

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that management will present at the following upcoming virtual investor conferences: Event: Stifel 2020 Virtual Healthcare Conference Date: Tuesday, November 17, 2020 Presentation Ti

• Compugen Reports Third Quarter 2020 Results

  11/5/2020

  - Initiated Phase 1/2 triple combination study to accelerate the direct evaluation of the DNAM axis hypothesis - Enrollment in COM701 Phase 1 monotherapy expansion cohort and Phase 1 COM902 dose escalation studies on track

• Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China

  11/2/2020

  New patent expands composition of matter and use protection for COM902 beyond the United States and Europe

• Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy

  10/27/2020

  Expression data suggest potential of PVRIG inhibition to enhance T cell priming and infiltration into both inflamed and less inflamed tumors

• Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020

  10/22/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020 before the U.S. financial markets open.

• Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board

  9/30/2020

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nils Lonberg , Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years of experience in the biopha

• Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

  9/8/2020

  Study accelerates evaluation of Compugen's DNAM axis hypothesis and biomarker strategy